You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
About a year ago, the California company received approval for the flow cytometer from the China National Medical Products Administration.
The company has also seen uptake of HemoScreen in Europe and Australia since PixCell began selling the portable hematology analyzer in those markets.
In a preliminary study, the group reported high accuracy for the detection of breast cancer within an hour by combining a fluorescence flow cytometer with fine-needle biopsies.
The company also said that preliminary full-year 2019 revenues are expected to be up 6 percent, with sample-to-answer revenues up more than 20 percent.
Cytek said the reagents consist of basic T, B, and NK cell cluster of differentiation markers used for lymphocyte subset detection.
The test, which will be developed using the companies' respective technologies, will be marketed by Biolidics following clinical validation.
The company posted higher total sales for the first half of its fiscal year 2020 on sales growth in both in Japan and internationally.
Called the "Ccheck Prostate Cancer Confirmation" test, Anixa's assay integrates flow cytometry and machine learning to identify evidence of cancer in a person's bloodstream.
Cytek said that the approval places the company on a path to offering a complete spectral flow cytometry solution — including instruments and reagents — to customers in China.
Rutgers researchers have developed a point-of-care tool that can rapidly assess the sensitivity of tumor cells to cancer drugs without staining or labeling.